This study shows that pembrolizumab can offer patients another treatment option to help keep their disease from coming back, extending the time that these patients are cancer-free makes a big difference in their quality of life.
The study found that postsurgical treatment with pembrolizumab was superior compared with observation, nearly doubling the length of time patients are cancer-free after surgery.
Many individuals with muscle-invasive bladder cancer can't take or refuse neoadjuvant chemotherapy, and others can't tolerate adjuvant treatments, highlighting the need for alternatives like pembrolizumab.
The results of this large clinical trial published in the New England Journal of Medicine demonstrate a significant advance in treatment options for high-risk muscle-invasive bladder cancer patients.
Collection
[
|
...
]